References
- Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355(9204): 637–45
- Willenheimer R, Dahlöf B, Rydberg E, et al. AT1-rreceptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J 1999; 20(14): 997–1008
- Goodfiend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334(25): 1649–54
- Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: A paradigm shift? Circulation 1994; 89(1): 493–8
- Müller DN, Luft FC. The reninangiotensin system in the vessel wall. Basic Res Cardiol 1998; 93 suppl 2: 7–14
- Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens 1994; 12 suppl 4: S3–10
- Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95(2): 651–7
- Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11 suppl 3: S13–8
- Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53
- Siragy H. Angiotensin II receptor blockers: review of the binding characteristics. Am J Cardiol 1999; 84(10A): 3–8S
- Gibbons GH. Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide. Clin Cardiol 1997; 20 11 suppl 2: II–18–25
- Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51(5): 820–45
- Chiolero A, Burnier M. Pharmacology of valsartan, an angiotensin II receptor antagonist. Expert Opin Invest Drug 1998; 7: 1915–25
- Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54(6): 885–902
- Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens 1997; 11 suppl 2: S91–5
- McClellan KJ, Markham A. Telmisartan. Drugs 1998; 56(6): 1039–44
- McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55(5): 713–8
- Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: Are there differences in efficacy? Am J Hypertens 2000; 13(4 Pt 1): 418–26
- Thurmann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98(19): 2037–42
- Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with Captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355(9215): 1582–7
- Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329(20); 1456–62
- Plum J, Bunten B, Nemeth R, et al. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998; 9(12): 2223–34
- Ebert LA, Falkenhain ME, Nahman NS Jr, et al. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999; 19(1): 1–6